Cargando…

Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting

PURPOSE: To assess the levels of quality of life (QoL) in major depressive disorder (MDD) patients treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic clinical setting mostly in the Middle East, East Asia, and Mexico....

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Jihyung, Novick, Diego, Montgomery, William, Moneta, Maria Victoria, Dueñas, Héctor, Peng, Xiaomei, Haro, Josep Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621215/
https://www.ncbi.nlm.nih.gov/pubmed/26527865
http://dx.doi.org/10.2147/PPA.S89870
_version_ 1782397403595276288
author Hong, Jihyung
Novick, Diego
Montgomery, William
Moneta, Maria Victoria
Dueñas, Héctor
Peng, Xiaomei
Haro, Josep Maria
author_facet Hong, Jihyung
Novick, Diego
Montgomery, William
Moneta, Maria Victoria
Dueñas, Héctor
Peng, Xiaomei
Haro, Josep Maria
author_sort Hong, Jihyung
collection PubMed
description PURPOSE: To assess the levels of quality of life (QoL) in major depressive disorder (MDD) patients treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic clinical setting mostly in the Middle East, East Asia, and Mexico. PATIENTS AND METHODS: Data for this post hoc analysis were taken from a 6-month prospective observational study involving 1,549 MDD patients without sexual dysfunction. QoL was measured using the EQ-5D instrument. Depression severity was measured using the Clinical Global Impression of Severity and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR(16)), while pain severity was measured using the pain items of the Somatic Symptom Inventory. Regression analyses were performed to compare the levels of QoL between duloxetine-treated (n=556) and SSRI-treated (n=776) patients, adjusting for baseline patient characteristics. RESULTS: These MDD patients, on average, had moderately impaired QoL at baseline, and the level of QoL impairment was similar between the duloxetine and SSRI groups (EQ-5D score of 0.46 [SD =0.32] in the former and 0.47 [SD =0.33] in the latter, P=0.066). Both descriptive and regression analyses confirmed QoL improvements in both groups during follow-up, but duloxetine-treated patients achieved higher QoL. At 24 weeks, the estimated mean EQ-5D score was 0.90 in the duloxetine cohort, which was statistically significantly higher than that of 0.83 in the SSRI cohort (P<0.001). Notably, pain severity at baseline was also statistically significantly associated with poorer QoL during follow-up (P<0.001). In addition, this association was observed in the subgroup of SSRI-treated patients (P<0.001), but not in that of duloxetine-treated patients (P=0.479). CONCLUSION: Depressed patients treated with duloxetine achieved higher QoL, compared to those treated with SSRIs, possibly in part due to its moderating effect on the link between pain and poorer QoL.
format Online
Article
Text
id pubmed-4621215
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46212152015-11-02 Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting Hong, Jihyung Novick, Diego Montgomery, William Moneta, Maria Victoria Dueñas, Héctor Peng, Xiaomei Haro, Josep Maria Patient Prefer Adherence Original Research PURPOSE: To assess the levels of quality of life (QoL) in major depressive disorder (MDD) patients treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic clinical setting mostly in the Middle East, East Asia, and Mexico. PATIENTS AND METHODS: Data for this post hoc analysis were taken from a 6-month prospective observational study involving 1,549 MDD patients without sexual dysfunction. QoL was measured using the EQ-5D instrument. Depression severity was measured using the Clinical Global Impression of Severity and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR(16)), while pain severity was measured using the pain items of the Somatic Symptom Inventory. Regression analyses were performed to compare the levels of QoL between duloxetine-treated (n=556) and SSRI-treated (n=776) patients, adjusting for baseline patient characteristics. RESULTS: These MDD patients, on average, had moderately impaired QoL at baseline, and the level of QoL impairment was similar between the duloxetine and SSRI groups (EQ-5D score of 0.46 [SD =0.32] in the former and 0.47 [SD =0.33] in the latter, P=0.066). Both descriptive and regression analyses confirmed QoL improvements in both groups during follow-up, but duloxetine-treated patients achieved higher QoL. At 24 weeks, the estimated mean EQ-5D score was 0.90 in the duloxetine cohort, which was statistically significantly higher than that of 0.83 in the SSRI cohort (P<0.001). Notably, pain severity at baseline was also statistically significantly associated with poorer QoL during follow-up (P<0.001). In addition, this association was observed in the subgroup of SSRI-treated patients (P<0.001), but not in that of duloxetine-treated patients (P=0.479). CONCLUSION: Depressed patients treated with duloxetine achieved higher QoL, compared to those treated with SSRIs, possibly in part due to its moderating effect on the link between pain and poorer QoL. Dove Medical Press 2015-10-16 /pmc/articles/PMC4621215/ /pubmed/26527865 http://dx.doi.org/10.2147/PPA.S89870 Text en © 2015 Hong et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Hong, Jihyung
Novick, Diego
Montgomery, William
Moneta, Maria Victoria
Dueñas, Héctor
Peng, Xiaomei
Haro, Josep Maria
Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
title Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
title_full Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
title_fullStr Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
title_full_unstemmed Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
title_short Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
title_sort health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621215/
https://www.ncbi.nlm.nih.gov/pubmed/26527865
http://dx.doi.org/10.2147/PPA.S89870
work_keys_str_mv AT hongjihyung healthrelatedqualityoflifeinpatientswithdepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorinanaturalisticoutpatientsetting
AT novickdiego healthrelatedqualityoflifeinpatientswithdepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorinanaturalisticoutpatientsetting
AT montgomerywilliam healthrelatedqualityoflifeinpatientswithdepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorinanaturalisticoutpatientsetting
AT monetamariavictoria healthrelatedqualityoflifeinpatientswithdepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorinanaturalisticoutpatientsetting
AT duenashector healthrelatedqualityoflifeinpatientswithdepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorinanaturalisticoutpatientsetting
AT pengxiaomei healthrelatedqualityoflifeinpatientswithdepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorinanaturalisticoutpatientsetting
AT harojosepmaria healthrelatedqualityoflifeinpatientswithdepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorinanaturalisticoutpatientsetting